Review



simnotrelvir sim0417  (Simcere Pharmaceutical Group)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Simcere Pharmaceutical Group simnotrelvir sim0417
    Simnotrelvir Sim0417, supplied by Simcere Pharmaceutical Group, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sim0417/sim0417/pm39349765-48-3-34
    Average 90 stars, based on 1 article reviews
    simnotrelvir sim0417 - by Bioz Stars, 2026-11
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19
    Article Snippet: I have read this protocol in its entirety and agree to conduct the study accordingly: Signature of Investigator: __________________________ Date: _____________ Printed Name: ___________________________ Investigator Title: ___________________________ Name/Address of Center: ___________________________ ___________________________ ___________________________ SIM0417 Jiangsu Simcere Pharmaceutical Co., Ltd. SIM0417-301 Confidential Version No: V7.0 Version Date: 2023/04/13 1 A Multicenter, Randomized, Double-blind, Phase II/III Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co- Administered with Ritonavir in Symptomatic Adult Participants with Mild to Moderate COVID-19 Confidentiality Statement This document is the property of Jiangsu Simcere Pharmaceutical Co., Ltd., or its subsidiaries.

    Article Title: Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19
    Article Snippet: SIM0417 Jiangsu Simcere Pharmaceutical Co., Ltd. SIM0417-301 Confidential Version No: V7.0 Version Date: 2023/04/13 79 • In principle, any female participant who becomes pregnant while participating in this study should discontinue the study drug immediately.

    Article Title: Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19
    Article Snippet: SIM0417 Jiangsu Simcere Pharmaceutical Co., Ltd. SIM0417-301 Confidential Version No: original protocol V1.0 Version Date: 2022/08/01 71 10.0 DATA MANAGEMENT

    Article Title: Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19
    Article Snippet: SIM0417 Jiangsu Simcere Pharmaceutical Co., Ltd. SIM0417-301 Confidential Version No: V7.0 Version Date: 2023/04/13 117 • If a female partner of a male subject becomes pregnant, the investigator will record the pregnancy information on the appropriate form and submit it to the Sponsor within 24 hours of learning of the partner’s pregnancy.

    Article Title: Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19
    Article Snippet: The use of stratification factors helped to IP: SIM0417 Protocol No: SIM0417-301 Jiansu Simcere Pharmaceutical Co., Ltd SAP: V 7.0 Version Date: 09FEB2023 16 / 57 Confidential balance the treatment group ratios within each stratum without restriction on the proportion of subjects within each stratum.

    Drug discovery:

    Article Title: Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19
    Article Snippet: .. SIM0417 Jiangsu Simcere Pharmaceutical Co., Ltd. SIM0417-301 Confidential Version No: original protocol V1.0 Version Date: 2022/08/01 20 Pharmacokinetics Analysis Set (PKS) All participants valid for mITT who received SIM0417 and with at least 1 quantifiable drug concentration collected after receiving the active study agent administration. ..

    Concentration Assay:

    Article Title: Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19
    Article Snippet: .. SIM0417 Jiangsu Simcere Pharmaceutical Co., Ltd. SIM0417-301 Confidential Version No: original protocol V1.0 Version Date: 2022/08/01 20 Pharmacokinetics Analysis Set (PKS) All participants valid for mITT who received SIM0417 and with at least 1 quantifiable drug concentration collected after receiving the active study agent administration. ..

    Clinical Proteomics:

    Article Title: Bioengineered amyloid peptide for rapid screening of inhibitors against main protease of SARS-CoV-2
    Article Snippet: .. Moreover, compounds like Pfizer’s PF-07304814 and Simcere’s SIM0417, designed to inhibit M pro , are currently undergoing clinical trials as potential oral treatments against SARS-CoV-2 – . ..



    Similar Products

    simnotrelvir sim0417  (Simcere Pharmaceutical Group)
    90
    Simcere Pharmaceutical Group simnotrelvir sim0417
    Simnotrelvir Sim0417, supplied by Simcere Pharmaceutical Group, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sim0417/sim0417/pm39349765-48-3-34
    Average 90 stars, based on 1 article reviews
    simnotrelvir sim0417 - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    xiannuoxintm simnotrelvir (sim0417)  (Simcere Pharmaceutical Group)
    90
    Simcere Pharmaceutical Group xiannuoxintm simnotrelvir (sim0417)
    3CLpro inhibitors in preclinical and clinical trials. The table provides an overview of 3CLpro inhibitors in preclinical and clinical trials. Each row represents a specific molecule under investigation, with information about the 3CLpro inhibitors’ name, the pharmaceutical company responsible for their development, the route of administration, the current state of development, the inhibitory concentration (IC 50 ) in nanomolar for 3CLpro inhibitors in preclinical trials, the effective concentration (EC 50 ) in micromolar for 3CLpro inhibitors in preclinical or clinical trials, and the unique identifier (ID) of the registered clinical trial. These data offer a comprehensive perspective on 3CLpro inhibitors in the research and development phase for potential use in treating COVID-19.
    Xiannuoxintm Simnotrelvir (Sim0417), supplied by Simcere Pharmaceutical Group, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sim0417/sim0417/pmc11209289-7-0-7
    Average 90 stars, based on 1 article reviews
    xiannuoxintm simnotrelvir (sim0417) - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    sim0417  (Simcere Pharmaceutical Group)
    90
    Simcere Pharmaceutical Group sim0417
    3CLpro inhibitors in preclinical and clinical trials. The table provides an overview of 3CLpro inhibitors in preclinical and clinical trials. Each row represents a specific molecule under investigation, with information about the 3CLpro inhibitors’ name, the pharmaceutical company responsible for their development, the route of administration, the current state of development, the inhibitory concentration (IC 50 ) in nanomolar for 3CLpro inhibitors in preclinical trials, the effective concentration (EC 50 ) in micromolar for 3CLpro inhibitors in preclinical or clinical trials, and the unique identifier (ID) of the registered clinical trial. These data offer a comprehensive perspective on 3CLpro inhibitors in the research and development phase for potential use in treating COVID-19.
    Sim0417, supplied by Simcere Pharmaceutical Group, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sim0417/sim0417/pmc10920794-25-7-6
    Average 90 stars, based on 1 article reviews
    sim0417 - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    3CLpro inhibitors in preclinical and clinical trials. The table provides an overview of 3CLpro inhibitors in preclinical and clinical trials. Each row represents a specific molecule under investigation, with information about the 3CLpro inhibitors’ name, the pharmaceutical company responsible for their development, the route of administration, the current state of development, the inhibitory concentration (IC 50 ) in nanomolar for 3CLpro inhibitors in preclinical trials, the effective concentration (EC 50 ) in micromolar for 3CLpro inhibitors in preclinical or clinical trials, and the unique identifier (ID) of the registered clinical trial. These data offer a comprehensive perspective on 3CLpro inhibitors in the research and development phase for potential use in treating COVID-19.

    Journal: Viruses

    Article Title: 3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2: Validation as a Molecular Target, Proposal of a Novel Catalytic Mechanism, and Inhibitors in Preclinical and Clinical Trials

    doi: 10.3390/v16060844

    Figure Lengend Snippet: 3CLpro inhibitors in preclinical and clinical trials. The table provides an overview of 3CLpro inhibitors in preclinical and clinical trials. Each row represents a specific molecule under investigation, with information about the 3CLpro inhibitors’ name, the pharmaceutical company responsible for their development, the route of administration, the current state of development, the inhibitory concentration (IC 50 ) in nanomolar for 3CLpro inhibitors in preclinical trials, the effective concentration (EC 50 ) in micromolar for 3CLpro inhibitors in preclinical or clinical trials, and the unique identifier (ID) of the registered clinical trial. These data offer a comprehensive perspective on 3CLpro inhibitors in the research and development phase for potential use in treating COVID-19.

    Article Snippet: XiannuoxinTM: Simnotrelvir (SIM0417) and Ritonavir (SSD8432) , Simcere , Oral , Phase II/III , 9 , 34 , NCT05373433 [ ] .

    Techniques: Clinical Proteomics, Concentration Assay